New Delhi [India], May 4 (ANI): Hyderabad-based pharma company Bharat Biotech has sought permission from the Drugs Controller General of India (DCGI) to conduct trials of Covaxin as COVID-19 vaccine booster dose in the 2-18 age group, sources said.
Hyderabad (Telangana) [India], December 30 (ANI): Hyderabad based vaccine manufacturer Bharat Biotech on Thursday announced that Covaxin (BBV152) has been found to be "safe, well-tolerated, and immunogenic" in the age group of 2-18 years in phase II/III study, said a company's statement.
New Delhi [India], May 19 (ANI): The Delhi High Court on Wednesday refused to put an interim stay on Phase 2-3 clinical trials of Covaxin COVID-19 vaccine for the 2-18 age group.
New Delhi [India], May 18 (ANI): Bharat Biotech is set to begin the phase II and III clinical trials for COVID-19 vaccine Covaxin in children in the age group of 2 to 18 years in the next 10-12 days, informed VK Paul, Member (Health), Niti Aayog on Tuesday.